STAT+: Lilly wins approval for once-weekly insulin shot

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. My delightful coworker, Jason Mast, is in Shanghai reporting for STAT. And that, my darling readers, is how you get access to the best biotech news anywhere. The need-to-know this morning Following a trial in a California federal court, a jury yesterday found that Eli Lilly breached a contract with Nektar Therapeutics to co-develop in good faith the autoimmune disease drug rezpeg. The jury awarded Nektar $90 million in damages plus interest, an amount far less than the company was seeking. Overton dodges senators on vaccines, abortion, China FDA commissioner nominee Heidi Overton largely avoided declaring her stance on several issues during a contentious Senate confirmation hearing yesterday, STAT’s Margaret Manto writes. She repeatedly pointed to existing law and agency policy when pressed on vaccines, abortion, and whether she would resist political pressure from President Trump or health secretary Robert F. Kennedy Jr. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in View All Plans To read the rest of this story subscribe to STAT+. Subscribe